Increasing Oral Medication Adherence for Metastatic Breast Cancer Patients

Last updated: December 17, 2024
Sponsor: European Institute of Oncology
Overall Status: Active - Recruiting

Phase

N/A

Condition

Breast Cancer

Cancer

Treatment

Decision Support System (DSS)

Standard care

Reminders

Clinical Study ID

NCT06726889
IEO 2014
  • Ages > 18
  • All Genders

Study Summary

Aim of this study is to optimize an adherence increasing intervention designed for metastatic Breast Cancer (BC) patients by applying a full factorial design in order to evaluate the optimal combination of three different intervention components.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with a diagnosis of metastatic BC

  • Patients with a prescription for any OAA (i.e. oral chemotherapy, endocrine therapy,and Cyclin-Dependent Kinase 4/6 Inhibitors)

  • Age >18 years old

  • Patients with a personal smart phone with internet access

  • Willingness and ability to comply with scheduled visits and other trial procedures

  • Understanding and speaking Italian language

  • Written informed consent

Exclusion

Exclusion Criteria:

  • Psychiatric disorders or conditions that might impair the ability to give informedconsent

  • Comorbidity that may impact on compliance to study procedures

Study Design

Total Participants: 104
Treatment Group(s): 4
Primary Treatment: Decision Support System (DSS)
Phase:
Study Start date:
January 25, 2024
Estimated Completion Date:
April 30, 2025

Study Description

Today different types of Oral Anticancer Agents (OAA) are commonly prescribed to Breast Cancer (BC) patients. Patients are reported to prefer the oral modality of administration over the intravenous one for its convenience, flexibility, and easier assumption; nonetheless, the phenomenon of medication non-adherence is well-documented.

Although several interventions have been designed and tested in order to foster medication adherence among BC patients, the great majority of them were focused on adherence to endocrine therapy for early-stage BC patients, with only few exceptions involving metastatic BC patients or considering adherence to other types of OAA.

The aim of this work is to optimize an adherence increasing intervention designed for metastatic BC patients. This will be achieved by applying a full factorial design in order to evaluate the optimal combination of three different intervention components (informative documentation, personalized reminders and feedback).

Connect with a study center

  • European Institute of Oncology

    Milan, 20141
    Italy

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.